Literature DB >> 20934725

Reproducibility of left atrial ablation with high-intensity focused ultrasound energy in a calf model.

Nestor R Villamizar1, Jennifer H Crow, Valentino Piacentino, Louis R DiBernardo, Mani A Daneshmand, Dawn E Bowles, Mark A Groh, Carmelo A Milano.   

Abstract

OBJECTIVE: Achieving transmural tissue ablation might be necessary for successful treatment of atrial fibrillation. The purpose of this study was to evaluate the reproducibility of transmural left atrial ablation using a high-intensity focused ultrasound energy system in a calf model.
METHODS: Nine heparinized bovines underwent a beating-heart left atrial ablation with a single application of the high-intensity focused ultrasound device. All animals were acutely killed, and the left atrium was fixed in formalin. Protocolized histological sections (5 μm) were obtained throughout each lesion and prepared with Masson trichrome and hematoxylin and eosin staining. Measurements were performed on a total of 359 slides from the 9 lesions. In addition, fresh left atrial tissues from 18 unused human donor hearts that did not meet the criteria for cardiac transplantation were measured at the site where the high-intensity focused ultrasound device is normally applied.
RESULTS: Calf left atrial thickness ranged between 2.5 and 20.1 mm, with a mean of 9.10 mm. High-intensity focused ultrasound ablation consistently produced a 100% transmural lesion in left atrial thickness up to 6 mm. In addition, a transmural lesion was observed in 91% of tissues that were up to 10 mm thick and in 85% that were up to 15 mm thick. Human left atrial thickness ranged between 1.2 to 6 mm, with a mean of 3.7 mm.
CONCLUSIONS: Calf left atrial thickness in this study was greater than human left atrial thickness. Human left atrial thickness is generally less than 6 mm, and in this range high-intensity focused ultrasound ablation achieved 100% transmurality. These histological results might correlate with a high success rate of atrial fibrillation ablation by using the high-intensity focused ultrasound system.
Copyright © 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20934725      PMCID: PMC4165600          DOI: 10.1016/j.jtcvs.2010.08.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures.

Authors:  Sunil M Prasad; Hersh S Maniar; Cindy J Camillo; Richard B Schuessler; John P Boineau; Thoralf M Sundt; James L Cox; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

2.  Evaluation of epicardial microwave ablation lesions: histology versus electrophysiology.

Authors:  Thomas J van Brakel; Gil Bolotin; Kenneth J Salleng; L Wiley Nifong; Maurits A Allessie; W Randolph Chitwood; Jos G Maessen
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

3.  Histopathology and transmurality of acute microwave lesions on the beating human atrium.

Authors:  Joseph W Turek; Louis R Dibernardo; Andrew J Lodge; Shu S Lin; R Duane Davis; Carmelo A Milano; Sinan A Simsir
Journal:  Interact Cardiovasc Thorac Surg       Date:  2006-03-22

4.  Cryosurgery for cardiac arrhythmias: acute and chronic effects on coronary arteries.

Authors:  W L Holman; M Ikeshita; R M Ungerleider; P K Smith; R E Ideker; J L Cox
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

5.  Reaction of the myocardium and coronary arteries to cryosurgery.

Authors:  E M Mikat; D B Hackel; L Harrison; J J Gallagher; A G Wallace
Journal:  Lab Invest       Date:  1977-12       Impact factor: 5.662

6.  Laser energy source in surgical atrial fibrillation ablation: preclinical experience.

Authors:  Mathews R Williams; Jennifer M Casher; Mark J Russo; Kimberly N Hong; Michael Argenziano; Mehmet C Oz
Journal:  Ann Thorac Surg       Date:  2006-12       Impact factor: 4.330

Review 7.  Surgical ablation devices for atrial fibrillation.

Authors:  Shelly C Lall; Ralph J Damiano
Journal:  J Interv Card Electrophysiol       Date:  2007-12       Impact factor: 1.900

8.  The architecture of the left lateral atrial wall: a particular anatomic region with implications for ablation of atrial fibrillation.

Authors:  José Angel Cabrera; Siew Yen Ho; Vicente Climent; Damián Sánchez-Quintana
Journal:  Eur Heart J       Date:  2008-02       Impact factor: 29.983

9.  Embolic complications associated with radiofrequency catheter ablation. Atakr Investigator Group.

Authors:  M R Epstein; L D Knapp; M Martindill; J A Lulu; J K Triedman; H Calkins; S K Huang; E P Walsh; J P Saul
Journal:  Am J Cardiol       Date:  1996-03-15       Impact factor: 2.778

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  3 in total

1.  Electrophysiological study 6 months after Epicor™ high-intensity focused ultrasound atrial fibrillation ablation.

Authors:  Rodrigue Garcia; Frédéric Sacher; Pierre Oses; Nicolas Derval; Laurent Barandon; Arnaud Denis; Mélèze Hocini; Xavier Roques; Michel Haïssaguerre; Louis Labrousse; Pierre Jaïs
Journal:  J Interv Card Electrophysiol       Date:  2014-11-09       Impact factor: 1.900

2.  Electrophysiological changes correlated with temperature increases induced by high-intensity focused ultrasound ablation.

Authors:  Ziqi Wu; Ronald E Kumon; Jacob I Laughner; Igor R Efimov; Cheri X Deng
Journal:  Ultrasound Med Biol       Date:  2014-12-13       Impact factor: 2.998

3.  Human comparative experimental study of surgical treatment of atrial fibrillation by epicardial techniques.

Authors:  Jean-Marc El Arid; Thomas Sénage; Claire Toquet; Ousama Al Habash; Antoine Mugniot; Olivier Baron; Jean-Christian Roussel
Journal:  J Cardiothorac Surg       Date:  2013-05-31       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.